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OPEN
ORIGINAL ARTICLE
Middle East respiratory syndrome coronavirus M
protein suppresses type I interferon expression through
the inhibition of TBK1-dependent phosphorylation
of IRF3
Pak-Yin Lui1,*, Lok-Yin Roy Wong1,*, Cheuk-Lai Fung1, Kam-Leung Siu1, Man-Lung Yeung2, Kit-San Yuen1,
Chi-Ping Chan1, Patrick Chiu-Yat Woo2, Kwok-Yung Yuen2 and Dong-Yan Jin1
Middle East respiratory syndrome coronavirus (MERS-CoV) infection has claimed hundreds of lives and has become a global
threat since its emergence in Saudi Arabia in 2012. The ability of MERS-CoV to evade the host innate antiviral response may
contribute to its severe pathogenesis. Many MERS-CoV-encoded proteins were identiﬁed to have interferon (IFN)-antagonizing
properties, which correlates well with the reduced IFN levels observed in infected patients and ex vivo models. In this study, we
fully characterized the IFN-antagonizing property of the MERS-CoV M protein. Expression of MERS-CoV M protein suppressed
type I IFN expression in response to Sendai virus infection or poly(I:C) induction. This suppressive effect was found to be
speciﬁc for the activation of IFN regulatory factor 3 (IRF3) but not nuclear factor-κB. MERS-CoV M protein interacted with
TRAF3 and disrupted TRAF3–TBK1 association leading to reduced IRF3 activation. M proteins from MERS-CoV and SARS-CoV
have three highly similar conserved N-terminal transmembrane domains and a C-terminal region. Using chimeric and truncation
mutants, the N-terminal transmembrane domains of the MERS-CoV M protein were found to be sufﬁcient for its inhibitory effect
on IFN expression, whereas the C-terminal domain was unable to induce this suppression. Collectively, our ﬁndings suggest a
common and conserved mechanism through which highly pathogenic MERS-CoV and SARS-CoV harness their M proteins to
suppress type I IFN expression at the level of TBK1-dependent phosphorylation and activation of IRF3 resulting in evasion of the
host innate antiviral response.
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INTRODUCTION
Middle East respiratory syndrome coronavirus (MERS-CoV) was ﬁrst
identiﬁed in Saudi Arabia in September 2012 as a novel coronavirus
that causes severe acute respiratory disease.1 Since then, this virus has
caused recurrent outbreaks in the Arabian Peninsula and has spread,
occasionally, to other parts of the world.2–9 According to the World
Health Organization, 1626 laboratory-conﬁrmed cases were reported
between September 2012 and 7 January 7 2016 with 586 related deaths
in 26 countries.10 In particular, 186 people were infected and 36 were
killed in one recent outbreak in South Korea.10 MERS-CoV is
classiﬁed into lineage C of Betacoronavirus and is most phylogenetically
related to two bat coronaviruses, HKU4 and HKU5, providing insight
on its evolutionary origin.11,12
MERS-CoV is a polycistronic positive-sense single-stranded RNA
virus with a genome of ~ 30 Kb in size. The 5′ most two-thirds of
MERS-CoV genome encodes polyproteins 1a and 1ab, which are
further cleaved to yield 16 non-structural proteins, whereas the 3′ end
of the genome encodes several structural or lineage-speciﬁc proteins.13
Upon infection, these proteins are expressed to facilitate viral
replication and propagation in the host.14 MERS-CoV infection has
been widely reported to mildly induce type I interferons (IFNs),
including IFN-α and -β, in patients as well as in animal and cellular
infection models.15–21 This has been attributed to the IFN-
antagonizing property of some MERS-CoV-encoded proteins, which
directly perturb the host IFN production mechanisms,22–26 lending
support to the notion that MERS-CoV uses multiple strategies to
evade the innate immune response.
In non-specialized epithelial cells as well as a subset of specialized
immune cells that are susceptible to MERS-CoV infection,16,18,27 type
I IFN production is an important part of the host innate immune
response and is initiated by ubiquitously expressed cytoplasmic viral
sensors in the retinoic acid-inducible gene-I (RIG-I)-like receptor
(RLR) family in response to the detection of viral pathogen-associated
molecular patterns such as double-stranded RNA (dsRNA).28,29
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Stimulated RLRs mobilize downstream signal transducers that lead to
the activation of the transcription factors IFN regulatory factor 3
(IRF3) and nuclear factor-κB (NF-κB) that drive IFN-β expression.28
The transduction events within this signaling cascade are prone to
negative regulation by many MERS-CoV proteins. In a comparative
analysis of MERS-CoV structural and accessory proteins, it has been
shown that M, ORF4a, ORF4b and ORF5 possess IFN-antagonizing
properties.22 We, and others, have characterized the ORF4a protein as
a dsRNA-binding protein that interferes with the activation of RLR by
either a dsRNA ligand or the protein co-activator PACT.24,25 However,
the molecular mechanisms through which other MERS-CoV proteins
manipulate the RLR signaling pathway to disrupt IFN-β expression
have not been elucidated.
In this study, we focused on the characterization of the MERS-CoV
M protein in IFN antagonism. Coronavirus M protein is a transmem-
brane glycoprotein localized predominantly to the Golgi complex and
is required for virion assembly.30–32 MERS-CoV M protein is of
particular interest because SARS-CoV M protein also inhibits IFN
production through a mechanism by which the formation of
TRAF3·TANK·TBK1/IKK-ε complex is impeded to ablate the activa-
tion of IRF3 transcription factor.30 In contrast, M protein encoded by
human coronavirus HKU1 associated with common cold has no
inﬂuence on IFN production.32 Here we reported that the MERS-CoV
M protein also speciﬁcally inhibited IRF3 activation but not NF-κB
signaling. MERS-CoV M protein was capable of interacting with
TRAF3 adapter protein and hampered TRAF3–TBK1 interaction
leading to diminished IRF3 activation. Using a chimeric protein
containing the MERS-CoV M protein N-terminal transmembrane
domains and a dormant SARS-CoV M protein C-terminal domain, we
conﬁrmed that the N-terminal transmembrane domains of MERS-
CoV M protein sufﬁciently account for its inhibitory effect. Although
another chimera containing SARS-CoV M protein N-terminal trans-
membrane domains and a MERS-CoV M protein C-terminal domain
was fully competent in IFN antagonism, a truncation mutant lacking
the functional ﬁrst transmembrane domain of SARS-CoV M was not,
suggesting that the C-terminal domain of the MERS-CoV M protein is
largely dispensable for its immunosuppressive activity.
MATERIALS AND METHODS
Plasmids
The IFNβ-luc reporter plasmid and RIG-I expression plasmid are gifts
from Professor Takashi Fujita (Kyoto University, Kyoto, Japan).28 The
expression plasmids for TBK1, IRF3 and TRAF3 were generous gifts
from Dr Genhong Cheng (University of California, Los Angeles, CA,
USA),33,34 whereas those for RIG-I N, IKK-ε and MAVS and IκB-α as
well as IRF3-luc and κB-luc reporter plasmids have been described
elsewhere.30,35–37
Viral RNA was extracted from MERS-CoV-infected Vero-E6
cells. The M gene was PCR-ampliﬁed from complementary DNA
and cloned into the EcoRI/XhoI sites of pCAGEN plasmid with the
addition of a C-terminal V5-tag with the following primers: 5′-ATG
TCT AAT ATG ACG CAA CTC ACT GA-3′ (forward) and 5′-AGC
TCG AAG CAA TGC AAG TTC-3′ (reverse). The SARS-CoV M
protein expression plasmid has been described elsewhere.30,32 The
expression plasmids for the SN and MN chimeras were constructed
by assembly PCR with the following forward primers covering the
breakpoints: 5′-AGG CTG TTT GCT CGT ACC CGC TCA TGG
TGG TCA TTC AAT CCT GAG-3′ (SN) and 5′-CCG GCT GTT TAT
GAG AAC TGG ATC AAT GTG GTC ATT CAA CCC A-3′ (MN).
The reverse primers were complementary to their respective forward
primers. The truncation mutant of the SN chimera lacking the ﬁrst
transmembrane domain was constructed using the forward primer:
5′-ATG GTA ACA CTT GCT TGT TTT GTG CT-3′.
Antibodies
Mouse anti-FLAG (M2) and anti-β-actin antibodies were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Mouse anti-V5 and anti-HA
(Y11) antibodies were purchased from Life Technologies (Grand Island,
NY, USA) and Santa Cruz Biotechnology (Dallas, TX, USA), respec-
tively. Rabbit anti-IRF3 and anti-phospho-IRF3 (Ser 386) antibodies
were purchased from IBL-America (Minneapolis, MN, USA).
Cell culture and Sendai virus
HEK-293 human embryonic kidney cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium with 10% fetal bovine serum
(Life Technologies) at 37 °C in a humidiﬁed chamber supplemented
with 5% carbon dioxide. Plasmid transfection was performed with
GeneJuice (Merck Millipore; Billerica, MA, USA). poly(I:C) was
purchased from Sigma-Aldrich and was transfected with Lipofectamine
2000 (Life Technologies). Sendai virus (Cantell strain) was purchased
from American Type Culture Collection (Manassas, VA, USA).
Reporter and protein assays
Dual-luciferase reporter assay, co-immunoprecipitation and western
blotting were performed as previously described.30,38 Particularly,
relative luciferase activity in arbitrary units was calculated by normal-
izing ﬁreﬂy luciferase activity to Renilla luciferase activity recovered
from cell lysate. Non-denaturing native polyacrylamide gel electro-
phoresis (PAGE) was performed as previously described.36,39,40
Bioinformatic analysis
Sequence alignment was performed using Cluster Omega, an online
tool based on the hidden Markov model,41 and hosted by the EMBL-
EBI server (http://www.ebi.ac.uk/Tools/msa/clustalo/). Transmem-
brane domain prediction was performed using TMFinder, which
considers hydrophobicity and helicity of the amino-acid sequence
(http://tmﬁnder.research.sickkids.ca/).42
RESULTS
Inhibition of IFN expression by MERS-CoV M protein mediated
through IRF3
To characterize the MERS-CoV M protein in terms of its IFN
antagonism, M protein was ectopically expressed in cultured cells for
functional assays (Figure 1A). A luciferase reporter construct driven by
IFN-β promoter was used to reﬂect IFN-β promoter activity stimulated
during infection. Sendai virus was used as a model virus to potently
induce IFN expression in transfected cells. When increasing doses of M
proteins were expressed in advance, a dose-dependent inhibition of
IFN-β promoter activity was observed (Figure 1B; bars 3–5 compared
with bar 2). A similar observation was also noted when synthetic
dsRNA analog poly(I:C) was used as an alternative inducer that
speciﬁcally stimulates the RLR pathway of IFN production (Figure 1C;
bars 3–5 compared with bar 2). These two pieces of data are generally
consistent with a previous report,22 and they further strengthen the
current model of the IFN antagonism of MERS-CoV M protein.
Cellular IFN-β expression is under the control of multiple
transcription factors, which work cooperatively to form a large
enhanceosome complex.43 In particular, IRF3 and NF-κB are two
transcription factors that are primarily activated by RLR
signaling.28,44,45 MERS-CoV M protein has previously been shown
to have no inﬂuence on NF-κB activation induced by Sendai virus
infection.22 However, it remains to be seen whether the MERS-CoV M
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protein could preferentially inhibit IRF3 and NF-κB signaling after
RIG-I activation. To address this issue, two different luciferase reporter
constructs, in which tandem copies of either IRF3- or NF-κB-binding
elements were inserted into their promoter region, were used. The
truncation mutant of RIG-I known as RIG-I N that contains only the
N-terminal CARD domain was chosen to be the inducer in these
assays because it is constitutively active and highly competent to induce
these two pathways.28 The MERS-CoV M protein was able to suppress
the promoter activity of the IRF3-driven luciferase construct in a
dose-dependent manner (Figure 2A; bars 3–5 compared with bar 2),
but no inhibitory effect was observed with the NF-κB-driven
construct (Figure 2B; bars 3–5 compared with bar 2) although
the canonical inhibitor IκB-α could efﬁciently blunt its activation as
a positive control (Figure 2B; bar 6 compared with bar 2). Hence, the
suppressive effect of the MERS-CoV M protein is speciﬁc for IRF3
signaling but not NF-κB activation.
Inhibition of IRF3 activation by the MERS-CoV M protein at
TRAF3–TBK1 level
To delineate the action point of the MERS-CoV M protein in IFN
antagonism, we tested the ability of the M protein to inhibit the
activation signal induced by different signal transducers of the RLR
pathway individually. The activation signal will be mostly unaffected if
the activation event mediated by that transducer is downstream of the
action point where M protein exerts its inhibitory effect. As described
above, RIG-I N is a constitutively active mutant that resembles
Figure 1 MERS-CoV M protein inhibits IFN-β expression stimulated by Sendai virus infection or poly(I:C) induction. Increasing doses of V5-tagged M protein
expression plasmid (MERS M-V5) were transfected into HEK-293 cells. (A) Western blotting (WB) was performed with an anti-V5 antibody to conﬁrm M
protein expression in cell lysates. β-Actin was also used as an internal loading control. (B, C) M expression plasmid was co-transfected with a ﬁreﬂy luciferase
reporter plasmid driven by the IFN-β promoter (IFNβ-luc) and a control Renilla luciferase reporter plasmid. After 24 h, cells were challenged with either
Sendai virus infection (SeV; 100 hemagglutinating units per mL) in B or poly(I:C) induction (1 μL/mL) in C for 16 h before harvest for dual-luciferase reporter
assay. Bars represent the mean of three biological replicates (n=3) and error bars indicate their s.d. The statistical signiﬁcance between selected samples
was evaluated using a two-tailed Student's t-test for unpaired samples with equal variance and P-value (P) was indicated.
Figure 2 MERS-CoV M protein suppresses IRF3 activation but not NF-κB signaling. An expression plasmid for dominant-active RIG-I N mutant containing
the N-terminal domain of RIG-I alone was used as a potent IFN inducer and co-transfected with an M expression plasmid and a ﬁreﬂy luciferase plasmid
driven by tandem copies of (A) IRF3-binding elements (IRF3-luc) or (B) κB elements (κB-luc) as well as the control Renilla luciferase plasmid. A canonical
NF-κB inhibitor IκB-α (IκB) was included as a positive control for the inhibition of NF-κB activity. Cells were collected at 40 h post transfection for dual-
luciferase reporter assay. Bars represent the mean of three biological replicates (n=3) and error bars indicate their s.d. The statistical signiﬁcance between
selected samples was evaluated using a two-tailed Student’s t-test for unpaired samples with equal variance and P-value (P) was indicated. retinoic acid-
inducible gene-I, RIG-I.
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immediate activation of virus sensor RIG-I after the detection of viral
infection. Although the M protein could mildly suppress IFN-β
promoter activation induced by RIG-I N at a marginally signiﬁcant
level, a dose-dependent effect was coarsely observed (Figure 3A; bars
3–5 compared with bar 2). A similar result was also obtained using
MAVS as an activator (Figure 3B; bars 3–5 compared with bar 2),
which is a mitochondrial adapter that diverts the activation signal
from RIG-I to the IRF3 and NF-κB pathways.44–47 When activators
committed to the IRF3 pathway were used, greater inhibitory effects
were observed, as in the cases of TBK1 (Figure 3C; bars 3–5 compared
with bar 2) and IKK-ε (Figure 3D; bars 3–5 compared with bar 2),
which are kinases which recognize and phosphorylate IRF3 as direct
substrate.48–51 Surprisingly, when a constitutively active mutant of IRF3
transcription factor (IRF3 5D), with ﬁve inducible phosphorylation
sites at Ser/Thr residues mutated to Asp,52 was employed, the
expression of the M protein no longer quenched the IRF3-induced
activation of IFN-β promoter (Figure 3E), suggesting that the inhibitory
effect of M protein occurs upstream of IRF3 activation.
To further analyze the molecular mechanism and consequences
through which MERS-CoV M protein exerts its inhibitory effect, we
ﬁrst investigated what signal transducer molecule might interact
with the M protein. Several RLR transducers were ectopically
expressed with MERS-CoV M protein in cultured cells for a co-
immunoprecipitation experiment. When the transducers were pre-
cipitated with an anti-FLAG antibody, the M protein was only detected
in TRAF3-containing precipitate (Figure 4A; lane 4 compared with
lanes 1–3) even though M protein was abundantly expressed in all
samples with other transducers (Figure 4A; lower panel for input),
Figure 3 The inhibitory effect of the MERS-CoV M protein occurs upstream of IRF3 activation. (A–E) HEK-293 cells were transfected with increasing doses
of the MERS M-V5 expression plasmid, a ﬁreﬂy luciferase reporter plasmid driven by IFN-β promoter (IFNβ-luc) and a control Renilla luciferase reporter
plasmid, together with different expression plasmids of RLR pathway activators, RIG-I N in A, mitochondrial adapter MAVS in B, IRF3 kinases TBK1 and IKK-
ε in C and D as well as a dominant-active IRF3 mutant (IRF3 5D) in E. Cells were collected after 40 h for dual-luciferase reporter assay. Bars represent the
mean of three biological replicates (n=3) and error bars indicate their s.d. The statistical signiﬁcance between selected samples was evaluated using a two-
tailed Student’s t-test for unpaired samples with equal variance and P-value (P) was indicated. Retinoic acid-inducible gene-I, RIG-I; RIG-I-like receptor, RLR.
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indicating the physical association between MERS-CoV M protein
and TRAF3.
TRAF3 functions as an adapter that bridges the mitochondrial
transducer MAVS with the downstream signaling complex containing
TBK1 and IKK-ε kinases that are essential for IRF3 activation.34,53 The
physical association of the MERS-CoV M protein with TRAF3
(Figure 4A) prompted us to test whether the adapter function of
TRAF3 would be particularly affected by M protein. We performed
another co-immunoprecipitation experiment to explore the possibility
that M protein could perturb the interaction of TRAF3 with the
downstream transducer complex. When TRAF3 and TBK1 were
ectopically expressed in cultured cells, the detection of TBK1 in
TRAF3-immunoprecipitate conﬁrmed the speciﬁc recruitment of
TBK1 to TRAF3 in the absence of M protein (Figure 4B; lane 2
compared with lane 1). However, when M protein was added to the
system, the interaction between TRAF3 and TBK1 was signiﬁcantly
disrupted (Figure 4B; lane 3 compared with lane 2), demonstrating
that the physical association of MERS-CoV M protein with TRAF3
perturbs TRAF3–TBK1 interaction.
It was observed that MERS-CoV M protein disrupted TRAF3–TBK1
interaction (Figure 4B), which is required for IRF3 activation. We then
evaluated whether IRF3 activation would be affected by the expression
of M protein. IRF3 dimerization visualized by non-denaturing native
PAGE is a sensitive assay for evaluating direct IRF3 activation.39
Therefore, we ectopically expressed IRF3 and M protein with the
inducer RIG-I N in cultured cells and subjected cell lysates directly to
native PAGE to check for IRF3 dimerization. When the inducer RIG-I
N was exclusively co-expressed with IRF3, the detection of an
additional slow-migrating band indicated the activation and dimeriza-
tion of IRF3, which would otherwise be entirely in its monomeric
form in the absence of any activator (Figure 4C; lane 2 compared with
lane 1). Interestingly, when M protein was expressed, the signal
reﬂecting the dimeric form of IRF3 molecules was signiﬁcantly
diminished, even though the total IRF3 level expressed in all samples
was highly comparable as detected by conventional denaturing SDS-
PAGE (Figure 4C; lower panel for SDS-PAGE), suggesting that IRF3
activation was greatly inhibited by the MERS-CoV M protein. IRF3
phosphorylation was also suppressed with the expression of MERS M
protein in a similar experimental setup (Figure 4D; lane 3 compared
with lane 2). Together with other results, MERS-CoV M protein was
thought to interact with TRAF3 to perturb TRAF3–TBK1 interaction,
which, in turn, affects IRF3 phosphorylation and activation.
Requirement and sufﬁciency of the N-terminal transmembrane
domains of MERS-CoV M protein for its innate
immunosuppressive effect
Given that the M proteins of both SARS-CoV and MERS-CoV were
capable of antagonizing IFN production through highly similar
Figure 4 MERS-CoV M protein binds with TRAF3 adapter and perturbs TRAF3–TBK1 interaction. (A) HEK-293 cells were transfected with plasmids
expressing MERS M-V5 protein and different FLAG-tagged wild-type RLR pathway activators (FLAG-RIG-I, -MAVS and -TRAF3). An empty vector was used as
a negative control in lane 1. Cells were collected after 40 h for a co-immunoprecipitation experiment with anti-FLAG antibody. The bound fraction of
immunoprecipitates (IP) as well as total cell lysate (as input) were analyzed by western blotting (WB) with anti-FLAG and anti-V5 antibodies. (B) HEK-293
cells were transfected with different combinations of expression plasmids for MERS M-V5, FLAG-tagged TRAF3 and HA-tagged TBK1, and collected after
40 h for co-immunoprecipitation experiment with an anti-FLAG antibody to assay for TBK1 recruitment using an anti-HA antibody. (C, D) HEK-293 cells were
transfected with different combinations of expression plasmids for wild-type IRF3, RIG-I N, and MERS M-V5. After 40 h, IRF3 dimerization from cell lysates
was visualized by non-denaturing native PAGE followed by western blotting with anti-IRF3 antibodies (C). IRF3 phosphorylation was also probed with anti-
phopho-IRF3 antibodies (D). The expression level of the ectopically expressed proteins was also individually veriﬁed in denaturing SDS-PAGE with respective
antibodies. The relative band intensity (*/#) of co-immunoprecipitated TBK1 in B, dimeric IRF3 in C or phospho-IRF3 (p-IRF3) in D for each sample was
measured using ImageJ software. Retinoic acid-inducible gene-I, RIG-I; RIG-I-like receptor, RLR.
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mechanisms,30 it will be of interest to analyze the sequence and
domain architecture of the two proteins. Sequence alignment of SARS-
CoV and MERS-CoV M proteins revealed a strikingly high sequence
similarity (470%) and the presence of three transmembrane domains
at the N-termini (Figure 5A). According to the prediction results, we
have initially constructed two truncation mutants for MERS-CoV M
protein, an N-terminal transmembrane domain-containing mutant
and a C-terminal mutant, and tested their inhibitory capacity in
suppressing IFN-β expression using a luciferase reporter assay.
However, neither exhibited an inhibitory effect (data not shown),
possibly due to unstable expression or aberrant localization.
To overcome the inactivity of truncation mutants and to deﬁne the
inhibitory activity of different domains, we decided to create chimeric
proteins using domain swapping between MERS-CoV and SARS-CoV
M proteins. Particularly, the SN chimera contains the N-terminal
transmembrane domains from SARS-CoV M protein and the C-term-
inal domain from MERS-CoV M protein, whereas the MN chimera
contains the N-terminal transmembrane domains from the MERS-
CoV M protein and the C-terminal domain from the SARS-CoV M
protein (Figure 5B). The breakpoint was designed to occur immedi-
ately after the third predicted transmembrane domain at residue 106
and before the conserved Ser residue in both proteins at residue 107
(Figure 5B).
We next compared the inhibitory effect of these two chimeras and
the full-length M proteins on IFN-β expression using the luciferase
reporter assay. Our previous study showed that the IFN-antagonizing
activity of the SARS-CoV M protein is mediated by its N-terminal
transmembrane domains, but the C-terminal domain has no effect.32
Figure 5 The N-terminal transmembrane domains of the MERS-CoV M protein are sufﬁcient for while its C-terminal domain is devoid of the innate
immunosuppressive effect. (A) Sequence alignment of MERS-CoV and SARS-CoV M proteins. An asterisk (*) denotes identical residues. A colon (:) and a
period (.) represent amino acids with highly and weakly similar physicochemical properties, respectively. The three predicted transmembrane (TM1-3)
domains are indicated below the sequences. (B) Diagrammatic representation of full-length MERS-CoV and SARS-CoV M proteins (MERS M-FL and SARS
M-FL) as well as two chimeras (SN and MN) constructed by swapping the N-terminal and C-terminal domains of the two M proteins with each other. The
predicted transmembrane domains and the residue numbers at the breakpoints are indicated. (C) HEK-293 cells were co-transfected with plasmids
expressing the indicated chimeric protein or the respective full-length M protein together with a TBK1 expression plasmid, a ﬁreﬂy luciferase reporter plasmid
driven by IFN-β promoter (IFNβ-luc) and a control Renilla luciferase reporter plasmid. Cells were collected after 40 h for dual-luciferase reporter assay. Bars
represent the mean of three biological replicates (n=3) and error bars indicate their s.d. (D) HEK-293 cells were transfected with plasmids expressing V5-
MN and FLAG-TRAF3 proteins. An empty vector was used as a negative control in lane 1. Cells were collected after 40 h for a co-immunoprecipitation
experiment with an anti-FLAG antibody. The bound fraction of immunoprecipitates (IP) as well as total cell lysate (as input) were analyzed by western blotting
(WB) with anti-FLAG and anti-V5 antibodies. (E) Diagrammatic representation of chimeric SN full-length (FL) protein and TM1-deletion (ΔTM1) truncation
mutant in the upper panel. Inhibition of IFN-β promoter activity by chimeric SN FL or ΔTM1 proteins was measured by luciferase reporter assay in the
bottom-left panel as in C. The expression levels of these two proteins were visualized with anti-V5 antibody. β-Actin was also probed as an internal loading
control in the bottom-right panel.
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When we swapped the C-terminal domain of the SARS-CoV M
protein with that of the MERS-CoV M protein in the SN chimera, a
similar suppressive effect on IFN-β promoter activity was observed
(Figure 5C; bar 4 compared with bar 3), consistent with our previous
results.32 Likewise, when we swapped the C-terminal domain of
MERS-CoV M with that of SARS-CoV M protein in MN, the chimera
was capable of suppressing IFN-β promoter activity to comparable
level (Figure 5C; bar 8 compared with bar 7). Given that the
C-terminal domain of SARS-CoV M protein possesses no suppressive
effect,32 the inhibitory activity of the MN chimera would be
predominantly due to the N-terminal domains of MERS-CoV M
protein. A biochemical assay also conﬁrmed that the MN chimera
maintained the ability to interact with the TRAF3 adapter protein in a
co-immunoprecipitation experiment (Figure 5D; lane 2 compared
with lane 1). Therefore, we concluded that the N-terminal transmem-
brane domains of the MERS-CoV M protein are required and
sufﬁcient for its innate immunosuppressive activity.
To further determine whether the C-terminal domain of the MERS
M protein also possesses IFN-antagonizing activity, we utilized the
knowledge that the ﬁrst transmembrane domain of SARS-CoV M
protein is fully responsible for its suppression effect32 to construct a
truncation mutant lacking the ﬁrst transmembrane domain in the SN
chimera and tested its effect on IFN-β expression using the luciferase
reporter assay. This truncation mutant, designated SN ΔTM1,
contains only the second and the third transmembrane domains of
SARS-CoV M protein at the N terminus fused with the C-terminal
domain of MERS-CoV M protein (Figure 5E; upper panel). While the
full-length chimeric SN protein was fully competent in suppressing
IFN-β promoter activity induced by TBK1, the removal of the ﬁrst
transmembrane domain of SARS-CoV M largely abolished its
inhibitory capability (Figure 5E; bottom-left panel, bar 4 compared
with bar 3), although both proteins were expressed to a detectable level
in cells (Figure 5E; bottom-right panel). It is therefore proposed that
the C-terminal domain of MERS-CoV M protein is devoid of and
largely dispensable for the IFN-antagonizing activity of MERS-CoV M
protein.
DISCUSSION
In this study, we reported that the MERS-CoV M protein inhibited
IRF3 activation, hence IFN expression, by disrupting TRAF3–TBK1
interaction. This innate immunosuppressive activity of the MERS-CoV
M protein was due to its conserved N-terminal transmembrane
domains. Our mechanistic study complemented the previous work
that showed that MERS-CoV M protein had IFN-antagonizing
activity.22 Both studies demonstrated that MERS-CoV M protein
suppressed IRF3 activity but not NF-κB signaling. It is known that the
activation of RIG-I and MAVS results in the activation of both IRF3
and NF-κB.28,44–46 Our results indicated that the MERS-CoV M
protein was capable of differentially suppressing the RIG-I-induced
activation of IRF3 (Figure 2). This provides further support to the
bifurcation of IRF3 and NF-κB signaling subsequent to RIG-I and
MAVS activation. Further investigations should elucidate the mechan-
ism by which the MERS-CoV M protein preferentially modulates IRF3
activators such as TBK1, while sparing NF-κB activators such as
CARD9.47 We provided evidence that the TRAF3–TBK1 interaction as
well as IRF3 phosphorylation and dimerization were affected by the
MERS-CoV M protein (Figure 4). Our ﬁndings ﬁll the knowledge gap
by providing novel mechanistic insight into the innate immunosup-
pressive activity of MERS-CoV M protein.
In our study, TRAF3 was also shown to interact with the MERS-
CoV M protein (Figure 4A). In line with this, the adapter function of
TRAF3 in TBK1 recruitment and subsequent IRF3 activation was
perturbed by MERS-CoV M protein (Figures 4B–D), which plausibly
contributed to the IFN antagonism of the MERS-CoV M protein
(Figures 1–3). The MERS-CoV M protein is a transmembrane protein
that was shown to co-localize with markers of the Golgi apparatus and
endoplasmic reticulum (ER)–Golgi intermediate compartments in the
perinuclear area.22 Although TRAF3 is known to adapt the mitochon-
drial transducer MAVS, it is not associated with mitochondria but rather
with the Golgi apparatus and ER–Golgi intermediate compartments in
unstimulated conditions,30,54 rendering it susceptible to interaction with
the MERS-CoV M protein. Upon stimulation with ligands or viral
infection, TRAF3 appears on membrane-bound fragments originating
from Golgi. Retention of TRAF3 in ER-to-Golgi compartments and
inability to form Golgi fragments rendered IFN-β expression
inefﬁcient.54 Therefore, whether TRAF3-containing Golgi fragment
formation is affected by MERS-CoV M protein warrants further analysis.
This may serve as a novel mechanism by which virus-encoded proteins
counteract host IFN production.
MERS-CoV and SARS-CoV are two highly pathogenic corona-
viruses that have caused hundreds of deaths. On one hand, the
development of relevant prophylactic and therapeutic agents has been
well under way.55–57 On the other hand, the identiﬁcation of the
pathogenic factors in these viruses is also in full swing. The M protein
is a pathogenic factor by virtue of its IFN-antagonizing property. Both
the MERS-CoV and SARS-CoV M proteins were found to suppress
IFN production with a highly similar mechanism in which the IRF3-
phosphorylating complex of TRAF3·TANK·TBK1/IKK-ε was affected
by their N-terminal transmembrane domains.30,32 Interestingly, in the
case of community-acquired human coronavirus HKU1, which
normally causes common cold in infected individuals, its M protein
showed no IFN antagonistic property,32 further supporting the
importance of the M protein in SARS-CoV and MERS-CoV patho-
genesis. Using a side-by-side comparison of SARS-CoV and MERS-
CoV M proteins, we discovered that the extent by which the MERS-
CoV M protein suppressed IFN-β promoter activity was lower than
that by SARS-CoV M protein. This difference might be explained
by the strengths of the interaction of MERS-CoV M protein with other
transducers. Whereas the MERS-CoV M protein was found to be
strongly associated with TRAF3, its interaction with TBK1 or IKK-ε was
undetectable (data not shown). This distinguished MERS-CoV M
protein from the SARS-CoV M protein, which interacts potently with
every component of the TRAF3·TANK·TBK1/IKK-ε complex.30 Further
investigations are required to shed light on how the interaction of the M
protein with TRAF3 complex might inﬂuence MERS-CoV pathogenesis.
Coronaviruses encode multiple proteins to counteract the host
innate antiviral response.58–60 MERS-CoV is no exception. Several
MERS-CoV-encoded proteins have been identiﬁed to be IFN
antagonists. We, and others, have characterized at least three
IFN-antagonizing proteins encoded by MERS-CoV. In addition to
the M protein reported in this study, ORF4a is a dsRNA-binding
protein, which directly inhibits RLR activation induced by dsRNA
and/or the protein co-activator PACT.24,25 In addition, our unpub-
lished data also revealed that ORF4b is a potent IFN antagonist. This is
in line with ﬁndings by other groups although the mechanistic details
of its action have not well documented.22,23 One recent report
suggested that ORF4b might not only interact directly with TBK1/
IKKε in the cytoplasm but also perturb IFN production in the nucleus
through an as yet unknown mechanism.61 Nevertheless, how M,
ORF4a, ORF4b and the other IFN-antagonizing proteins of MERS-
CoV coordinate with each other to modulate the host innate antiviral
response to facilitate viral replication and propagation remains elusive.
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